
~~WHAT IS CLAIMED IS~~CLAIMS

1. Use of a compound of Formula (I) in the manufacture of a medicament for use in a method of the prophylactic treatment of chemotherapy-induced peripheral neuropathy in a subject,



(I),

wherein

R_1, R_2, and R_3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NR_AR_B, and (NR_AR_B)carbonyl;


A is a nonaromatic 4, 5, 6, 7, or 8-membered ring that contains 1 or 2 nitrogen atoms and, optionally, one sulfur or oxygen atom, wherein the nonaromatic ring is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, cyano, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, heteroaryl, heteroarylalkyl, hydroxy, hydroxyalkyl, nitro, NR_CR_D, (NR_CR_D)alkyl, (NR_CR_D)carbonyl, (NR_CR_D)carbonylalkyl, (NR_CR_D)sulfonyl, and oxo; and

R_A, R_B, R_C, and R_D are independently selected from the group consisting of hydrogen, alkyl, and alkycarbonyl;


or a pharmaceutically acceptable salt or solvate thereof.

~~2. The use of claim 1, wherein the treatment is prophylactic treatment.~~

~~3~~2. The use of claim~~s~~ 1 ~~or 2~~, wherein A is selected from the group consisting of



and



.

43. The use of any of claims 1-32, wherein R^1, R^2, and R^3 are independently hydrogen or halogen;

R^6 is hydrogen; and

n is 0.

54. The use of any of claims 1-43, wherein the compound of formula (I) is 2-(2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide.

65. The use of any of claims 1-43, wherein the compound of formula (I) is 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide.

76. The use of any of claims 1-43, wherein the compound of formula (I) is 2-[(2S)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide.

87. The use of any of claims 1-76, wherein said treatment further comprises administration of one or more chemotherapeutic agents.

98. The ~~method~~ use of claim 87, wherein the chemotherapeutic agent or agents is utilized for the treatment of cancer.

109. The use of claims ~~8~~ 7 or 89, wherein the chemotherapeutic agent is selected from the group consisting of bortezomib, carboplatin, cisplatin, gemcitabine, misonidazole, oxaliplatin, procarbazine, thalidomide, docetaxel, hexamethylmelamine, paclitaxel, vincristine, vinblastine, or vinorelbine.

~~11. The use of any of claims 8-10, wherein the chemotherapeutic agent is carboplatin.~~

~~12. The use of any of claims 8-10, wherein the chemotherapeutic agent is cisplatin.~~

~~13. The use of any of claims 8-10, wherein the chemotherapeutic agent is paclitaxel.~~

~~14. The use of any of claims 8-10, wherein the chemotherapeutic agent is vinorelbine.~~

~~15. The use of any of claims 8-10, wherein the chemotherapeutic agents are cisplatin and docetaxel.~~

~~16. The use of any of claims 8-10, wherein the chemotherapeutic agents are carboplatin and docetaxel.~~

~~17. The use of any of claims 8-10, wherein the chemotherapeutic agents are cisplatin and gemcitabine.~~

~~18. The use of any of claims 8-10, wherein the chemotherapeutic agents are carboplatin and gemcitabine.~~

~~19~~10. The use of any of claims 8-~~18~~9, wherein the cancer is selected from the group consisting of ovarian cancer, cervical cancer, colorectal cancer, prostate cancer, breast cancer, testicular cancer, leukemia, neuroblastoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and non-small cell lung cancer.

~~20~~11. The use of any of claims 8-~~18~~9, wherein the cancer is selected from the group consisting of ovarian cancer, breast cancer, and non-small cell lung cancer.

~~21~~12. The use of any of claims 8-~~20~~11, wherein the compound of formula (I) is administered before the administration of the chemotherapeutic agent.

~~22~~13. The use of any of claims 8-~~20~~11, wherein the compound of formula (I) is administered during the administration of the chemotherapeutic agent.

~~23~~14. The use of any of claims 8-~~20~~11, wherein the compound of formula (I) is administered after the administration of the chemotherapeutic agent.